TrialSignal
Clinical trial intelligence report
A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03651947
Status
COMPLETED
Phase
Phase I
Sponsor
Qilu Pharmaceutical Co., Ltd.
Executive brief
Investment-Ready Snapshot
QL1206 is being developed by Qilu Pharmaceutical Co., Ltd. as a biosimilar to Xgeva® (Denosumab), targeting the treatment of conditions related to bone metabolism. The trial aimed to establish pharmacokinetic, safety, and pharmacodynamic similarities between QL1206 and Xgeva® in healthy adults.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03651947
Indication
Healthy People
Modality
monoclonal antibody
Target
QL1206, Xgeva®
Intervention
QL1206, Xgeva®
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.